{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:49:26Z","timestamp":1780364966020,"version":"3.54.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jiangxi Province College Student Innovation and Entrepreneurship Training Program Project","award":["No. 202310403036"],"award-info":[{"award-number":["No. 202310403036"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82260034"],"award-info":[{"award-number":["No. 82260034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"crossref","award":["No. 20242BAB25469"],"award-info":[{"award-number":["No. 20242BAB25469"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06315-6","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:02:38Z","timestamp":1758283358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia"],"prefix":"10.1007","volume":"151","author":[{"given":"Xing","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"issue":"1","key":"6315_CR1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12964-024-01995-y","volume":"22","author":"NMF Abdalsalam","year":"2024","unstructured":"Abdalsalam NMF, Ibrahim A, Saliu MA, Liu T-M, Wan X, Yan D (2024) MDSC: a new potential breakthrough in CAR-T therapy for solid tumors. Cell Commun Signal 22(1):612. https:\/\/doi.org\/10.1186\/s12964-024-01995-y","journal-title":"Cell Commun Signal"},{"issue":"5","key":"6315_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3343\/alm.2021.41.5.479","volume":"41","author":"A Ahn","year":"2021","unstructured":"Ahn A, Park C-J, Kim M-s, Cho Y-U, Jang S, Bae MH, Lee J-H, Lee J-H, Koh K-N, Im HJ (2021) Granulocytic and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia. Ann Lab Med 41(5):479\u2013484. https:\/\/doi.org\/10.3343\/alm.2021.41.5.479","journal-title":"Ann Lab Med"},{"issue":"12","key":"6315_CR3","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","volume":"105","author":"E Atallah","year":"2020","unstructured":"Atallah E, Schiffer CA (2020) Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica 105(12):2738\u20132745. https:\/\/doi.org\/10.3324\/haematol.2019.242891","journal-title":"Haematologica"},{"issue":"1","key":"6315_CR4","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7(1):12150. https:\/\/doi.org\/10.1038\/ncomms12150","journal-title":"Nat Commun"},{"issue":"7","key":"6315_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","volume":"32","author":"O Br\u00fcck","year":"2018","unstructured":"Br\u00fcck O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, Kovanen P, Aittokallio T, Koskenvesa P, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S (2018) Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. Leukemia 32(7):1643\u20131656. https:\/\/doi.org\/10.1038\/s41375-018-0175-0","journal-title":"Leukemia"},{"key":"6315_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fcell.2020.00351","volume":"8","author":"M Chaib","year":"2020","unstructured":"Chaib M, Chauhan SC, Makowski L (2020) Friend or foe? Recent strategies to target myeloid cells in cancer. Front Cell Dev Biol 8:351. https:\/\/doi.org\/10.3389\/fcell.2020.00351","journal-title":"Front Cell Dev Biol"},{"key":"6315_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104317","volume":"363","author":"KE Cole","year":"2021","unstructured":"Cole KE, Ly QP, Hollingsworth MA, Cox JL, Padussis JC, Foster JM, Vargas LM, Talmadge JE (2021) Human splenic myeloid derived suppressor cells: phenotypic and clustering analysis. Cell Immunol 363:104317. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104317","journal-title":"Cell Immunol"},{"issue":"1","key":"6315_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"G Das","year":"2013","unstructured":"Das G, Christiansson L, S\u00f6derlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B, Olsson-Str\u00f6mberg U, Loskog ASI (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in sokal high risk chronic myeloid leukemia. PLoS ONE 8(1):e55818. https:\/\/doi.org\/10.1371\/journal.pone.0055818","journal-title":"PLoS ONE"},{"issue":"8","key":"6315_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003005","volume":"9","author":"DG DeNardo","year":"2021","unstructured":"DeNardo DG, Galkin A, Dupont J, Zhou L, Bendell J (2021) GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. J Immunother Cancer 9(8):e003005. https:\/\/doi.org\/10.1136\/jitc-2021-003005","journal-title":"J Immunother Cancer"},{"issue":"17","key":"6315_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37060","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng Y, Shi M, Yi L, Naveed Khan M, Xia Z, Li X (2024) Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment. Heliyon 10(17):e37060. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37060","journal-title":"Heliyon"},{"key":"6315_CR11","doi-asserted-by":"publisher","first-page":"1016059","DOI":"10.3389\/fimmu.2022.1016059","volume":"13","author":"R Fan","year":"2022","unstructured":"Fan R, De Beule N, Maes A, De Bruyne E, Menu E, Vanderkerken K, Maes K, Breckpot K, De Veirman K (2022) The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Front Immunol 13:1016059. https:\/\/doi.org\/10.3389\/fimmu.2022.1016059","journal-title":"Front Immunol"},{"issue":"3","key":"6315_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1021\/acs.chemrev.7b00568","volume":"118","author":"G Ferrer-Sueta","year":"2018","unstructured":"Ferrer-Sueta G, Campolo N, Trujillo M, Bartesaghi S, Carballal S, Romero N, Alvarez B, Radi R (2018) Biochemistry of peroxynitrite and protein tyrosine nitration. Chem Rev 118(3):1338\u20131408. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00568","journal-title":"Chem Rev"},{"key":"6315_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.737364","volume":"11","author":"M Fresno","year":"2021","unstructured":"Fresno M, Giron\u00e8s N (2021) Myeloid-derived suppressor cells in Trypanosoma cruzi infection. Front Cell Infect Microbiol 11:737364. https:\/\/doi.org\/10.3389\/fcimb.2021.737364","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"6315_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.Cir-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3\u20138. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0297","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"6315_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/jcmm.13326","volume":"22","author":"C Giallongo","year":"2017","unstructured":"Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F (2017) Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. J Cell Mol Med 22(2):1070\u20131080. https:\/\/doi.org\/10.1111\/jcmm.13326","journal-title":"J Cell Mol Med"},{"key":"6315_CR16","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2023","unstructured":"Giannotta C, Autino F, Massaia M (2023) The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells. Front Immunol 13:1102471. https:\/\/doi.org\/10.3389\/fimmu.2022.1102471","journal-title":"Front Immunol"},{"issue":"9","key":"6315_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2015.1034918","volume":"4","author":"G Gunaydin","year":"2015","unstructured":"Gunaydin G, Kesikli SA, Guc D (2015) Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset. Oncoimmunology 4(9):e1034918. https:\/\/doi.org\/10.1080\/2162402x.2015.1034918","journal-title":"Oncoimmunology"},{"issue":"2","key":"6315_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M (2021) The functional crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the immunosuppressive tumor microenvironment. Cancers (Basel) 13(2):210. https:\/\/doi.org\/10.3390\/cancers13020210","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6315_CR19","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/s41598-021-97371-8","volume":"11","author":"I Harada","year":"2021","unstructured":"Harada I, Sasaki H, Murakami K, Nishiyama A, Nakabayashi J, Ichino M, Miyazaki T, Kumagai K, Matsumoto K, Hagihara M, Kawase W, Tachibana T, Tanaka M, Saito T, Kanamori H, Fujita H, Fujisawa S, Nakajima H, Tamura T (2021) Compromised anti-tumor\u2013immune features of myeloid cell components in chronic myeloid leukemia patients. Sci Rep 11(1):18046. https:\/\/doi.org\/10.1038\/s41598-021-97371-8","journal-title":"Sci Rep"},{"issue":"6","key":"6315_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3324\/haematol.2022.282005","volume":"108","author":"P Harrington","year":"2023","unstructured":"Harrington P, Dillon R, Radia D, Rousselot P, McLornan DP, Ong M, Green A, Verde A, Hussain F, Raj K, Kordasti S, Harrison C, De Lavallade H (2023) Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia. Haematologica 108(6):1555\u20131566. https:\/\/doi.org\/10.3324\/haematol.2022.282005","journal-title":"Haematologica"},{"key":"6315_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108821","volume":"109","author":"Y Hong","year":"2022","unstructured":"Hong Y, Wen R, Wu G, Li S, Liu W, Chen Z, Yang Z (2022) Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors. Int Immunopharmacol 109:108821. https:\/\/doi.org\/10.1016\/j.intimp.2022.108821","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"6315_CR22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.Cir-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, Rodriguez PC, Ochoa AC (2015) Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 3(11):1236\u20131247. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0036","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"6315_CR23","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"Y-C Hsieh","year":"2021","unstructured":"Hsieh Y-C, Kirschner K, Copland M (2021) Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia 35(5):1229\u20131242. https:\/\/doi.org\/10.1038\/s41375-021-01238-w","journal-title":"Leukemia"},{"issue":"6","key":"6315_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70231","volume":"6","author":"T Hu","year":"2025","unstructured":"Hu T, Zhai J, Yang Z, Peng J, Wang C, Liu X, Li Y, Yao J, Chen F, Li H, An T, Liu Z, Wang H (2025) Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations. MedComm 6(6):e70231. https:\/\/doi.org\/10.1002\/mco2.70231","journal-title":"MedComm"},{"key":"6315_CR25","doi-asserted-by":"publisher","first-page":"1226443","DOI":"10.3389\/fimmu.2023.1226443","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang J, Zhao Y, Zhao K, Yin K, Wang S (2023) Function of reactive oxygen species in myeloid-derived suppressor cells. Front Immunol 14:1226443. https:\/\/doi.org\/10.3389\/fimmu.2023.1226443","journal-title":"Front Immunol"},{"key":"6315_CR26","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM (2017) Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol 8:469. https:\/\/doi.org\/10.3389\/fimmu.2017.00469","journal-title":"Front Immunol"},{"issue":"9","key":"6315_CR27","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong ASM (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129(9):1166\u20131176. https:\/\/doi.org\/10.1182\/blood-2016-10-745992","journal-title":"Blood"},{"issue":"4","key":"6315_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","volume":"32","author":"A Ibrahim","year":"2025","unstructured":"Ibrahim A, Mohamady Farouk Abdalsalam N, Liang Z, Kashaf Tariq H, Li R, O. Afolabi L, Rabiu L, Chen X, Xu S, Xu Z, Wan X, Yan D (2025) MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther 32(4):371\u2013392. https:\/\/doi.org\/10.1038\/s41417-025-00886-9","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"6315_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/bjh.16718","volume":"191","author":"YD Irani","year":"2020","unstructured":"Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, Yeung DT, Ross DM, Hughes TP, Yong ASM (2020) Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol 191(3):433\u2013441. https:\/\/doi.org\/10.1111\/bjh.16718","journal-title":"Br J Haematol"},{"issue":"4","key":"6315_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13167-023-00348-y","volume":"14","author":"W Jia","year":"2023","unstructured":"Jia W, Gong X, Ye Z, Li N, Zhan X (2023) Nitroproteomics is instrumental for stratification and targeted treatments of astrocytoma patients: expert recommendations for advanced 3PM approach with improved individual outcomes. EPMA J 14(4):673\u2013696. https:\/\/doi.org\/10.1007\/s13167-023-00348-y","journal-title":"EPMA J"},{"issue":"13","key":"6315_CR31","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/jcm10132788","volume":"10","author":"S Kapor","year":"2021","unstructured":"Kapor S, Santibanez JF (2021) Myeloid-derived suppressor cells and mesenchymal stem\/stromal cells in myeloid malignancies. J Clin Med 10(13):2788. https:\/\/doi.org\/10.3390\/jcm10132788","journal-title":"J Clin Med"},{"key":"6315_CR32","doi-asserted-by":"publisher","first-page":"1495907","DOI":"10.3389\/fimmu.2025.1495907","volume":"16","author":"C Knickmeier","year":"2025","unstructured":"Knickmeier C, Noubissi Nzeteu GA, Gibbs BF, Hoogwater FJH, Nijkamp MW, Bockhorn M, Meyer NH (2025) It\u2019s about TIME \u2013 Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. Front Immunol 16:1495907. https:\/\/doi.org\/10.3389\/fimmu.2025.1495907","journal-title":"Front Immunol"},{"issue":"11","key":"6315_CR33","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/v16111746","volume":"16","author":"J Koki\u00e7i","year":"2024","unstructured":"Koki\u00e7i J, Preechanukul A, Arellano-Ballestero H, Gorou F, Peppa D (2024) Emerging insights into memory natural killer cells and clinical applications. Viruses 16(11):1746. https:\/\/doi.org\/10.3390\/v16111746","journal-title":"Viruses"},{"issue":"7","key":"6315_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158392","volume":"11","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Giallongo C, Romano A, Parrinello NL, La Cava P, Brundo MV, Bramanti V, Stagno F, Vigneri P, Chiarenza A, Palumbo GA, Tibullo D, Di Raimondo F (2016) Mesenchymal stem cells (MSC) regulate activation of granulocyte-like myeloid derived suppressor cells (G-MDSC) in chronic myeloid leukemia patients. PLoS ONE 11(7):e0158392. https:\/\/doi.org\/10.1371\/journal.pone.0158392","journal-title":"PLoS ONE"},{"issue":"22","key":"6315_CR35","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1182\/blood.2022017295","volume":"141","author":"V Krishnan","year":"2023","unstructured":"Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, Chan ZE, Yu M, Makheja M, Rayan NA, Lim MGL, Cheung AMS, Bari S, Chng WJ, Than H, Ouyang J, Rackham O, Tan TZ, Hwang WYK, Chuah C, Prabhakar S, Ong ST (2023) A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood 141(22):2738\u20132755. https:\/\/doi.org\/10.1182\/blood.2022017295","journal-title":"Blood"},{"issue":"4","key":"6315_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/bloodadvances.2024014592","volume":"9","author":"V Kuznetsova","year":"2025","unstructured":"Kuznetsova V, Krishnan V, Costa A, Ren X, Ricketts TD, Patel SB, Connelly AN, Goel P, Knapp JP, Franceski AM, Luca F, Lobo de Figueiredo-Pontes L, Bhatia R, Prabhakar S, Ong ST, Welner RS (2025) Chronic inflammation deters natural killer cell fitness and cytotoxicity in myeloid leukemia. Blood Adv 9(4):759\u2013773. https:\/\/doi.org\/10.1182\/bloodadvances.2024014592","journal-title":"Blood Adv"},{"issue":"8","key":"6315_CR37","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3390\/jpm11080697","volume":"11","author":"P Kwa\u015bnik","year":"2021","unstructured":"Kwa\u015bnik P, Giannopoulos K (2021) Treatment-free remission\u2014a new aim in the treatment of chronic myeloid leukemia. J Pers Med 11(8):697. https:\/\/doi.org\/10.3390\/jpm11080697","journal-title":"J Pers Med"},{"issue":"12","key":"6315_CR38","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/j.celrep.2016.11.062","volume":"17","author":"CR Lee","year":"2016","unstructured":"Lee CR, Kwak Y, Yang T, Han JH, Park SH, Ye MB, Lee W, Sim KY, Kang JA, Kim YC, Mazmanian SK, Park SG (2016) Myeloid-derived suppressor cells are controlled by regulatory T cells via TGF-\u03b2 during murine colitis. Cell Rep 17(12):3219\u20133232. https:\/\/doi.org\/10.1016\/j.celrep.2016.11.062","journal-title":"Cell Rep"},{"issue":"1","key":"6315_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 6(1):362. https:\/\/doi.org\/10.1038\/s41392-021-00670-9","journal-title":"Signal Transduct Target Ther"},{"key":"6315_CR40","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.3389\/fimmu.2019.02577","volume":"10","author":"M Lian","year":"2019","unstructured":"Lian M, Zhang J, Zhao L, Chen X, Peng Y, Wang Q, Chen S, Ma X (2019) Interleukin-35 regulates immune microenvironment of autoimmune hepatitis through inducing the expansion of myeloid-derived suppressor cells. Front Immunol 10:2577. https:\/\/doi.org\/10.3389\/fimmu.2019.02577","journal-title":"Front Immunol"},{"issue":"1","key":"6315_CR41","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7150\/ijbs.65402","volume":"18","author":"M Liu","year":"2022","unstructured":"Liu M, Zhang H, Zhang L, Liu X, Zhou S, Wang X, Zhong W, Zhang J, Wang B, Zhao J, Zhou L (2022) RIP3 blockade prevents immune-mediated hepatitis through a myeloid-derived suppressor cell dependent mechanism. Int J Biol Sci 18(1):199\u2013213. https:\/\/doi.org\/10.7150\/ijbs.65402","journal-title":"Int J Biol Sci"},{"key":"6315_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2016.06.018","volume":"85","author":"RL Lopes","year":"2016","unstructured":"Lopes RL, Borges TJ, Zanin RF, Bonorino C (2016) IL-10 is required for polarization of macrophages to M2-like phenotype by mycobacterial DnaK (heat shock protein 70). Cytokine 85:123\u2013129. https:\/\/doi.org\/10.1016\/j.cyto.2016.06.018","journal-title":"Cytokine"},{"issue":"1","key":"6315_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","volume":"13","author":"J Lu","year":"2024","unstructured":"Lu J, Luo Y, Rao D, Wang T, Lei Z, Chen X, Zhang B, Li Y, Liu B, Xia L, Huang W (2024) Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion. Exp Hematol Oncol 13(1):39. https:\/\/doi.org\/10.1186\/s40164-024-00505-7","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"6315_CR44","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.3390\/cancers13215435","volume":"13","author":"M Matsushita","year":"2021","unstructured":"Matsushita M (2021) Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells. Cancers 13(21):5435. https:\/\/doi.org\/10.3390\/cancers13215435","journal-title":"Cancers"},{"issue":"9","key":"6315_CR45","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1080\/10428194.2025.2495369","volume":"66","author":"MJ Mauro","year":"2025","unstructured":"Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE (2025) Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY. Leuk Lymphoma 66(9):1615\u20131624. https:\/\/doi.org\/10.1080\/10428194.2025.2495369","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6315_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00262-023-03614-0","volume":"73","author":"T Montecchi","year":"2024","unstructured":"Montecchi T, Nannini G, De Tommaso D, Cassioli C, Coppola F, Ringressi MN, Carraro F, Naldini A, Taddei A, Marotta G, Amedei A, Baldari CT, Ulivieri C (2024) Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression. Cancer Immunol Immunother 73(1):2. https:\/\/doi.org\/10.1007\/s00262-023-03614-0","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"6315_CR47","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J, Solenthaler M, Ochsenbein AF (2009) Programmed death 1 signaling on chronic myeloid leukemia\u2013specific T cells results in T-cell exhaustion and disease progression. Blood 114(8):1528\u20131536. https:\/\/doi.org\/10.1182\/blood-2008-09-179697","journal-title":"Blood"},{"issue":"1","key":"6315_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/imm.12876","volume":"154","author":"J Nan","year":"2018","unstructured":"Nan J, Xing YF, Hu B, Tang JX, Dong HM, He YM, Ruan DY, Ye QJ, Cai JR, Ma XK, Chen J, Cai XR, Lin ZX, Wu XY, Li X (2018) Endoplasmic reticulum stress induced LOX-1(+ ) CD15(+) polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology 154(1):144\u2013155. https:\/\/doi.org\/10.1111\/imm.12876","journal-title":"Immunology"},{"issue":"2","key":"6315_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4049\/jimmunol.1701019","volume":"200","author":"S Ostrand-Rosenberg","year":"2018","unstructured":"Ostrand-Rosenberg S, Fenselau C (2018) Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol 200(2):422\u2013431. https:\/\/doi.org\/10.4049\/jimmunol.1701019","journal-title":"J Immunol"},{"issue":"21","key":"6315_CR50","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.3390\/ijms20215459","volume":"20","author":"GA Palumbo","year":"2019","unstructured":"Palumbo GA, Parrinello NL, Giallongo C, D\u2019Amico E, Zangh\u00ec A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Di Raimondo F, Romano A (2019) Monocytic myeloid derived suppressor cells in hematological malignancies. Int J Mol Sci 20(21):5459. https:\/\/doi.org\/10.3390\/ijms20215459","journal-title":"Int J Mol Sci"},{"key":"6315_CR51","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jconrel.2023.09.050","volume":"363","author":"J Park","year":"2023","unstructured":"Park J, Nah Y, Kim WJ (2023) IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy. J Control Release 363:496\u2013506. https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.050","journal-title":"J Control Release"},{"issue":"2","key":"6315_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101380","volume":"5","author":"F Pettinella","year":"2024","unstructured":"Pettinella F, Mariotti B, Lattanzi C, Bruderek K, Donini M, Costa S, Marini O, Iannoto G, Gasperini S, Caveggion E, Castellucci M, Calzetti F, Bianchetto-Aguilera F, Gardiman E, Giani M, Dusi S, Cantini M, Vassanelli A, Pavone D, Milella M, Pilotto S, Biondani P, Hoing B, Schleupner MC, Hussain T, Hadaschik B, Kaspar C, Visco C, Tecchio C, Koenderman L, Bazzoni F, Tamassia N, Brandau S, Cassatella MA, Scapini P (2024) Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors. Cell Rep Med 5(2):101380. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101380","journal-title":"Cell Rep Med"},{"issue":"4","key":"6315_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.323","volume":"4","author":"R Ren","year":"2023","unstructured":"Ren R, Xiong C, Ma R, Wang Y, Yue T, Yu J, Shao B (2023) The recent progress of myeloid-derived suppressor cell and its targeted therapies in cancers. MedComm 4(4):e323. https:\/\/doi.org\/10.1002\/mco2.323","journal-title":"MedComm"},{"issue":"4","key":"6315_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.Can-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553\u20131560. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-1921","journal-title":"Cancer Res"},{"issue":"4","key":"6315_CR55","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s12288-024-01843-6","volume":"40","author":"F Saj","year":"2024","unstructured":"Saj F, Vasudevan Nampoothiri R, Lad D, Jandial A, Sachdeva MUS, Bose P, Varma N, Khadwal A, Prakash G, Malhotra P (2024) Prognostic significance of regulatory T-cells and PD-1 + CD8 T-cells in chronic myeloid leukemia patients treated with generic imatinib. Indian J Hematol Blood Transfus 40(4):580\u2013587. https:\/\/doi.org\/10.1007\/s12288-024-01843-6","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"3","key":"6315_CR56","doi-asserted-by":"publisher","DOI":"10.31083\/fbl25203","volume":"30","author":"JF Santibanez","year":"2025","unstructured":"Santibanez JF (2025) Myeloid-derived suppressor cells: implications in cancer immunology and immunotherapy. Front Biosci-Landmark 30(3):25203. https:\/\/doi.org\/10.31083\/fbl25203","journal-title":"Front Biosci-Landmark"},{"issue":"1","key":"6315_CR57","doi-asserted-by":"publisher","first-page":"2060907","DOI":"10.1080\/2162402x.2022.2060907","volume":"11","author":"M-T Su","year":"2022","unstructured":"Su M-T, Kumata S, Endo S, Okada Y, Takai T (2022) LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs. Oncoimmunology 11(1):2060907. https:\/\/doi.org\/10.1080\/2162402x.2022.2060907","journal-title":"Oncoimmunology"},{"issue":"1","key":"6315_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41467-021-27928-8","volume":"13","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Takaku T, Kitamura T (2022) Eliminating chronic myeloid leukemia stem cells by IRAK1\/4 inhibitors. Nat Commun 13(1):271. https:\/\/doi.org\/10.1038\/s41467-021-27928-8","journal-title":"Nat Commun"},{"issue":"1","key":"6315_CR59","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s12672-025-03138-2","volume":"16","author":"S Tavakoli","year":"2025","unstructured":"Tavakoli S, Samareh-Salavati M, Rahnama MA, Abdolahi S, Hassanzadeh A, Ghazvinian Z, Verdi J, Vousooghi N, Manoochehrabadi S, Chahardouli B, Barkhordar M, Seyhoun I, Ahmadvand M (2025) Natural killer cell therapy in hepatocellular carcinoma: a comprehensive review. Discov Oncol 16(1):1348. https:\/\/doi.org\/10.1007\/s12672-025-03138-2","journal-title":"Discov Oncol"},{"key":"6315_CR60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2019.00475","volume":"10","author":"S Tomi\u0107","year":"2019","unstructured":"Tomi\u0107 S, Joksimovi\u0107 B, Beki\u0107 M, Vasiljevi\u0107 M, Milanovi\u0107 M, \u010coli\u0107 M, Vu\u010devi\u0107 D (2019) Prostaglanin-E2 potentiates the suppressive functions of human mononuclear myeloid-derived suppressor cells and increases their capacity to expand IL-10-producing regulatory T cell subsets. Front Immunol 10:475. https:\/\/doi.org\/10.3389\/fimmu.2019.00475","journal-title":"Front Immunol"},{"issue":"1","key":"6315_CR61","doi-asserted-by":"publisher","first-page":"2478344","DOI":"10.1080\/16078454.2025.2478344","volume":"30","author":"T Toptas","year":"2025","unstructured":"Toptas T, Demirtas D, Yanik AM, Candan O, Arikan F, Salim S, Menguc M, Yilmaz AF, Tuglular T, Kaygusuz Atagunduz I (2025) Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia. Hematology 30(1):2478344. https:\/\/doi.org\/10.1080\/16078454.2025.2478344","journal-title":"Hematology"},{"key":"6315_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106273","volume":"88","author":"H Ureshino","year":"2020","unstructured":"Ureshino H, Shindo T, Kimura S (2020) Role of cancer immunology in chronic myelogenous leukemia. Leuk Res 88:106273. https:\/\/doi.org\/10.1016\/j.leukres.2019.106273","journal-title":"Leuk Res"},{"issue":"2","key":"6315_CR63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D (2018) Myeloid-derived suppressor cells coming of age. Nat Immunol 19(2):108\u2013119. https:\/\/doi.org\/10.1038\/s41590-017-0022-x","journal-title":"Nat Immunol"},{"issue":"7","key":"6315_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101848","volume":"9","author":"GL Volti","year":"2014","unstructured":"Volti GL, Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo GA, Stagno F, Vigneri P, Di Raimondo F (2014) Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear leukocytes (PMNs) in chronic myeloid Leukemia patients. PLoS ONE 9(7):e101848. https:\/\/doi.org\/10.1371\/journal.pone.0101848","journal-title":"PLoS ONE"},{"key":"6315_CR65","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Ding Y, Guo N, Wang S (2019) MDSCs: key criminals of tumor pre-metastatic niche formation. Front Immunol 10:172. https:\/\/doi.org\/10.3389\/fimmu.2019.00172","journal-title":"Front Immunol"},{"issue":"1","key":"6315_CR66","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","volume":"11","author":"S Wang","year":"2023","unstructured":"Wang S, Zhao X, Wu S, Cui D, Xu Z (2023) Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res 11(1):34. https:\/\/doi.org\/10.1186\/s40364-023-00475-8","journal-title":"Biomark Res"},{"issue":"5","key":"6315_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00432-024-05755-w","volume":"150","author":"K Wang","year":"2024","unstructured":"Wang K, Wang Y, Yin K (2024) Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies. J Cancer Res Clin Oncol 150(5):243. https:\/\/doi.org\/10.1007\/s00432-024-05755-w","journal-title":"J Cancer Res Clin Oncol"},{"issue":"44","key":"6315_CR68","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","volume":"8","author":"L Wu","year":"2017","unstructured":"Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H (2017) Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget 8(44):76843\u201376856. https:\/\/doi.org\/10.18632\/oncotarget.20164","journal-title":"Oncotarget"},{"key":"6315_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101794","volume":"38","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Li Z-Z, Zhong N-N, Cao L-M, Liu B, Bu L-L (2023) Charting new frontiers: co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care. Transl Oncol 38:101794. https:\/\/doi.org\/10.1016\/j.tranon.2023.101794","journal-title":"Transl Oncol"},{"issue":"1","key":"6315_CR70","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/10428194.2019.1658098","volume":"61","author":"H Xu","year":"2020","unstructured":"Xu H, Liu J, Shen N, Zhao Z, Cui J, Zhou S, Jiang L, Zhu X, Tang L, Liang H, Liu W, Zhu Z, Meng L, Zhu X (2020) The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia. Leuk Lymphoma 61(1):128\u2013137. https:\/\/doi.org\/10.1080\/10428194.2019.1658098","journal-title":"Leuk Lymphoma"},{"key":"6315_CR71","doi-asserted-by":"publisher","first-page":"1078118","DOI":"10.3389\/fimmu.2023.1078118","volume":"14","author":"D Yao","year":"2023","unstructured":"Yao D, Lai J, Lu Y, Zhong J, Zha X, Huang X, Liu L, Zeng X, Chen S, Weng J, Du X, Li Y, Xu L (2023) Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. Front Immunol 14:1078118. https:\/\/doi.org\/10.3389\/fimmu.2023.1078118","journal-title":"Front Immunol"},{"issue":"16","key":"6315_CR72","doi-asserted-by":"publisher","first-page":"1900037","DOI":"10.1002\/advs.201900037","volume":"6","author":"M Yu","year":"2019","unstructured":"Yu M, Duan X, Cai Y, Zhang F, Jiang S, Han S, Shen J, Shuai X (2019) Multifunctional nanoregulator reshapes immune microenvironment and enhances immune memory for tumor immunotherapy. Adv Sci 6(16):1900037. https:\/\/doi.org\/10.1002\/advs.201900037","journal-title":"Adv Sci"},{"issue":"1","key":"6315_CR73","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40164-022-00296-9","volume":"11","author":"S Yu","year":"2022","unstructured":"Yu S, Ren X, Li L (2022) Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. Exp Hematol Oncol 11(1):43. https:\/\/doi.org\/10.1186\/s40164-022-00296-9","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"6315_CR74","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12967-022-03528-y","volume":"20","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhou X, Guo J, Zhang F, Qian Y, Wang G, Duan M, Wang Y, Zhao H, Yang Z, Liu Z, Jiang X (2022) TA-MSCs, TA-MSCs-EVs, MIF: their crosstalk in immunosuppressive tumor microenvironment. J Transl Med 20(1):320. https:\/\/doi.org\/10.1186\/s12967-022-03528-y","journal-title":"J Transl Med"},{"issue":"7","key":"6315_CR75","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1007\/s00277-025-06495-8","volume":"104","author":"D Zhang","year":"2025","unstructured":"Zhang D, Li Y, Liu T, Liu X, Zhang J (2025a) Efficacy and safety analysis of different treatment regimens in newly diagnosed acute promyelocytic leukemia. Ann Hematol 104(7):3703\u20133711. https:\/\/doi.org\/10.1007\/s00277-025-06495-8","journal-title":"Ann Hematol"},{"key":"6315_CR76","doi-asserted-by":"publisher","first-page":"1621885","DOI":"10.3389\/fimmu.2025.1621885","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhao Y, Dong Y, Jiang X (2025b) NK cell-based immunotherapy strategies for myeloid leukemia. Front Immunol 16:1621885. https:\/\/doi.org\/10.3389\/fimmu.2025.1621885","journal-title":"Front Immunol"},{"key":"6315_CR77","doi-asserted-by":"publisher","first-page":"1157537","DOI":"10.3389\/fimmu.2023.1157537","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Du J, Shen X (2023) Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front Immunol 14:1157537. https:\/\/doi.org\/10.3389\/fimmu.2023.1157537","journal-title":"Front Immunol"},{"issue":"2","key":"6315_CR78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/ol.2020.12410","volume":"21","author":"H Zhou","year":"2020","unstructured":"Zhou H, Jiang M, Yuan H, Ni W, Tai G (2020) Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer (review). Oncol Lett 21(2):149. https:\/\/doi.org\/10.3892\/ol.2020.12410","journal-title":"Oncol Lett"},{"key":"6315_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216381","volume":"573","author":"R Zhou","year":"2023","unstructured":"Zhou R, Chen S, Wu Q, Liu L, Wang Y, Mo Y, Zeng Z, Zu X, Xiong W, Wang F (2023) CD155 and its receptors in cancer immune escape and immunotherapy. Cancer Lett 573:216381. https:\/\/doi.org\/10.1016\/j.canlet.2023.216381","journal-title":"Cancer Lett"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06315-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T20:46:46Z","timestamp":1761338806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":79,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6315"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06315-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"263"}}